P & F Sorscher

P30中心内的试点和可行性项目将有助于埃默里大学和 附属机构，加强师资建设，广泛利用科学核心，与 我们囊性纤维化(CF)研究计划的全球研究主题。坚定地致力于基本和 CF科学的翻译方面(特别是与NIDDK相关的疾病后遗症)，以及 这项提案描述了实质性的制度支持、动力和创新。基础设施和 试点项目的征集、审查和推进的方法已经到位，并且已经 在埃默里成功使用多年。P30试点和可行性部分将作为关键 囊性纤维化研究的智力环境中的要素已经确立并在不断发展 迅速地。试点和可行性部分的具体目标如下： 具体目标1.提供研究支持，使符合条件的调查人员能够探索可行性 针对CF基础生物医学、临床和翻译的创新、高风险概念 研究。项目通常持续两年，与P30的总体目标一致，并 预计将得到美国国立卫生研究院或其他资助机构的进一步赠款支持。 具体目标2.为试点和可行性的监督和审查提供行政框架 学习。这包括关于继续(或终止)P30计划试点的建议 指导委员会，征求和审查试点申请，关于赠款和 飞行员调查人员的手稿生产率，跟踪获奖者随后的职业事件，以及所有方面 项目管理。 根据研究节段型审查，推荐了两个试点项目和可行性项目作为NIH的资助项目 和提交材料中所述的优先顺序。提供了项目1的研究摘要(《作用》 炎症性肠损伤中的程序性细胞死亡(PCD)信号“)和项目2(深度表型 囊性纤维化相关糖尿病综合小分子组学和临床结果的研究“)。支持 通过NIH P30机制，将推动与NIDDK优先考虑的CF方面相关的新发现 发病机制及治疗。试点和可行性项目将在我们的 学院开发囊性纤维化的新的更好的治疗方法，并提供一个引擎来驱动创新。

Pilot and feasibility projects within the P30 Center will contribute to multidisciplinary research at Emory and affiliated institutions, enhance faculty development, extensively utilize scientific cores, and integrate well with the global research themes of our cystic fibrosis (CF) research program. A strong commitment to basic and translational aspects of CF science (and NIDDK-relevant sequelae of the disease in particular), together with substantial institutional support, momentum, and innovation, are described by this proposal. Infrastructure and methodologies for solicitation, review, and advancement of pilot projects are in place, and have been successfully utilized at Emory for many years. The P30 Pilot and Feasibility component will serve as a key element within an intellectual environment for cystic fibrosis research that is well-established and growing rapidly. Specific Aims of the Pilot and Feasibility component are as follows: Specific Aim 1. Provide research support that will enable eligible investigators to explore the feasibility of innovative, high-risk concepts directed towards CF basic biomedical, clinical, and translational research. Projects typically last two years, are concordant with the overall objectives of the P30, and are expected to result in further grant support from NIH or other funding agencies. Specific Aim 2. Provide an administrative framework for oversight and review of Pilot and Feasibility studies. This includes recommendations regarding continuation (or termination) of pilots to the P30 Program Steering Committee, solicitation and review of pilot applications, record-keeping with regard to grant and manuscript productivity of pilot investigators, tracking subsequent career events of awardees, and all aspects of program management. Two Pilot and Feasibility projects are recommended for NIH funding based on study section-type review and prioritization as described in the submission. Research summaries are provided for Project 1 (“Role of Programmed Cell Death (PCD) Signaling in Inflammatory Intestinal Injury”) and Project 2 (“Deep Phenotyping of Cystic Fibrosis-Related Diabetes Integrating Small Molecule -Omics and Clinical Outcomes”). Support through the NIH P30 mechanism will advance novel findings relevant to NIDDK-prioritized aspects of CF pathogenesis and treatment. Pilot and Feasibility projects will engage a long-standing passion among our faculty to develop novel and better therapies for cystic fibrosis, and furnish an engine to drive innovation.